Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyl Sulfoxide SCHEMBL16050126 | 0.81 | ALDH1A1 (0.61) | ALDH1A1 | |
| SCHEMBL49039 | 0.80 | — | — | |
| Dimethyl Sulfoxide SCHEMBL28706476 | 0.79 | ALDH1A1 (0.57) | ALDH1A1 | |
| SCHEMBL29989468 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL27895817 | 0.76 | — | — | |
| Methyl Alcohol SCHEMBL6261246 | 0.72 | — | — | |
| Dimethyl Sulfoxide SCHEMBL3962475 | 0.71 | — | — | |
| Dimethyl Sulfoxide SCHEMBL5964425 | 0.71 | — | — | |
| Benzene SCHEMBL28325455 | 0.69 | ALDH1A1 (0.43) | ALDH1A1 | |
| Methylene Chloride SCHEMBL1249920 | 0.67 | ALDH1A1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216699-A1 | SEMI-SYNTHETIC GLYCOPEPTIDES HAVING ANTIBACTERIAL ACTIVITY | LEAD THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2008140973-A1 | SEMI-SYNTHETIC GLYCOPEPTIDES WITH ANTIBACTERIAL ACTIVITY | LEAD THERAPEUTICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7163924-B2 | Ketolide derivatives | CHIRON CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1670808-A1 | ANTIMICROBIAL DERIVATIVES | CHIRON CORPORATION (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1618119-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050153905-A1 | Novel ketolide derivatives | CHIRON CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050101548-A1 | Antimicrobial derivatives | LIN XIAODONG (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005028493-A1 | ANTIMICROBIAL DERIVATIVES | CHIRON CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | ALDH1A1 2876/4885 |
| US-20100216699-A1 | SEMI-SYNTHETIC GLYCOPEPTIDES HAVING ANTIBACTERIAL ACTIVITY | ASNS, ALG1, ALG8 | ALDH1A1 3289/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | ALDH1A1 4150/4885 |
| US-20050153905-A1 | Novel ketolide derivatives | KHK, CYP51A1, SI | ALDH1A1 1182/4885 |
| US-20050101548-A1 | Antimicrobial derivatives | CFTR, VIP, Q6ZSR9 | ALDH1A1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.